Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -44,989 | -24,061 | -111,566 | -159,307 | -42,220 |
| Depreciation Amortization | 647 | 325 | 1,371 | 1,005 | 674 |
| Accounts payable and accrued liabilities | 2,365 | 3,980 | -2,295 | -1,065 | 2,123 |
| Other Working Capital | -3,984 | 298 | -18,012 | -13,164 | -5,793 |
| Other Operating Activity | 4,659 | -340 | 57,484 | 115,630 | 6,264 |
| Operating Cash Flow | $-41,302 | $-19,798 | $-73,018 | $-56,901 | $-38,952 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -341 | -140 | -3,869 | -3,852 | -3,852 |
| Purchase Sale Intangibles | N/A | N/A | -3,500 | -3,500 | N/A |
| Other Investing Activity | 0 | 0 | -3,483 | -3,490 | 0 |
| Investing Cash Flow | $-341 | $-140 | $-7,352 | $-7,342 | $-3,852 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 39,550 | N/A | N/A |
| Debt Repayment | N/A | N/A | -43,000 | N/A | N/A |
| Common Stock Issued | 70,507 | 26 | 140,858 | 141,281 | 550 |
| Other Financing Activity | -61 | -48 | -1,015 | -640 | -543 |
| Financing Cash Flow | $70,446 | $-22 | $136,393 | $140,641 | $7 |
| Beginning Cash Position | 146,540 | 146,540 | 90,517 | 90,517 | 90,517 |
| End Cash Position | 175,343 | 126,580 | 146,540 | 166,915 | 47,720 |
| Net Cash Flow | $28,803 | $-19,960 | $56,023 | $76,398 | $-42,797 |
| Free Cash Flow | |||||
| Operating Cash Flow | -41,302 | -19,798 | -73,018 | -56,901 | -38,952 |
| Capital Expenditure | -341 | -140 | -3,869 | -3,852 | -3,852 |
| Free Cash Flow | -41,643 | -19,938 | -76,887 | -60,753 | -42,804 |